临床因素与血清蛋白联合评分可预测高级别浆液性卵巢癌复发时间
OBJECTIVE: To investigate the utility of a combined panel of protein biomarkers and clinical factors to predict recurrence in serous ovarian cancer patients. METHODS: Women at Augusta University diagnosed with ovarian cancer were enrolled between 2005 and 2015 (n = 71).…
要点
- 26种蛋白中脑源性神经营养因子和血小板衍生生长因子分子在单变量和多变量分析中均对无进展生存期有显著预测作用。
- 该模型命名为浆液性高级别卵巢癌(SHOC)评分,作者认为可用于预测缓解期患者预后。
核心结论
- SHOC评分可预测缓解期高级别浆液性卵巢癌患者的预后。
- 作者希望该工具有助于对注定复发的缓解期患者进行早期干预和巩固治疗策略。
研究设计与样本
- 研究纳入2005至2015年奥古斯塔大学诊断的卵巢癌女性71例,入组时及随访时抽血。
- 缓解期血清用SOMAscan阵列检测35例的1129种蛋白水平。
- 筛选出的26种最佳蛋白用Luminex在同一35例及另36例(合计71例)中做正交验证。
- 26种蛋白数据与临床因素用弹性网多变量模型组合,寻找预测无进展生存期的最佳组合。
主要发现
- 26种蛋白中脑源性神经营养因子和血小板衍生生长因子分子在单变量和多变量分析中均对无进展生存期有显著预测作用。
- 该模型命名为浆液性高级别卵巢癌(SHOC)评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the utility of a combined panel of protein biomarkers and clinical factors to predict recurrence in serous ovarian cancer patients. METHODS: Women at Augusta University diagnosed with ovarian cancer were enrolled between 2005 and 2015 (n = 71). Blood was drawn at enrollment and follow-up visits. Patient serum collected at remission was analyzed using the SOMAscan array (n = 35) to measure levels of 1129 proteins. The best 26 proteins were confirmed using Luminex assays in the same 35 patients and in an additional 36 patients (ntotal = 71) as orthogonal validation. The data from these 26 proteins was combined with clinical factors using an elastic net multivariate model to find an optimized combination predictive of progression-free survival (PFS). RESULTS: Of the 26 proteins, Brain Derived Neurotrophic Factor and Platelet Derived Growth Factor molecules were significant for predicting PFS on both univariate and multivariate analyses. All 26 proteins were combined with clinical factors using the elastic net algorithm. Ten components were determined to predict PFS (HR of 6.55, p-value 1.12 × 10-6, CI 2.57-16.71). This model was named the serous high grade ovarian cancer (SHOC) score. CONCLUSION: The SHOC score can predict patient prognosis in remission. This tool will hopefully lead to early intervention and consolidation therapy strategies in remission patients destined to recur.
引用
- Mysona D, Pyrzak A, Purohit S, et al. A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer. Gynecol Oncol. 2018. PMID: 30578005. doi:10.1016/j.ygyno.2018.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。